Renal Cancer Clinical Trial
— EMERALDOfficial title:
Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence: A Prospective, Monocentric, Randomized, Comparative and Open-label Study
Verified date | March 2020 |
Source | University Hospital, Grenoble |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with renal cancer are commonly treated by robot-assisted partial nephrectomy. Renal artery clamping is commonly required inducing kidney ischemia during surgery. It impacts parenchymal and renal function. This study aims to compare a new surgical procedure in order to reduce ischemia effect and preserve renal function after partial nephrectomy for renal tumour.
Status | Active, not recruiting |
Enrollment | 31 |
Est. completion date | December 1, 2020 |
Est. primary completion date | February 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - candidate for a robot-assisted partial nephrectomy for renal tumour - patient affiliated to social security - signature of the informed consent Exclusion Criteria: - proven or suspected allergy to the indocyanine green - coagulation disorder contraindicating robot assistance in the partial nephrectomy - medical pathology contraindicating pneumo-peritoneum - multiple tumors - horseshoe kidney - exclusion period of another interventionnal study - protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health |
Country | Name | City | State |
---|---|---|---|
France | University Hospital Grenoble-Alps (CHU-GA) | La Tronche |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble | Clinical Investigation Centre for Innovative Technology Network, Intuitive Surgical |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Benefit on postoperative renal function of fluorescence-enhanced super-selective clamping during robot assisted partial nephrectomy compared with robot-assisted partial nephrectomy with renal artery clamping | The glomerular filtration rate (GFR) of the kidney operated is assessed at 6 months after surgery. This value is compared to that assessed before the surgery to see the variation. This variation is compare between the two groups. | 6 months | |
Secondary | Number of group conversion in the zero ischemia method. | The feasibility of the new technique is assessed by counting the number of group conversion towards conventional technique. | 6 months | |
Secondary | Surgical duration in the two groups | Duration between the first incision and the skin closure | 6 months | |
Secondary | Complications | number of complications per and post-surgery up to 1 month | 1 month | |
Secondary | Per-surgery blood loss | per-surgery blood loss in millimeter | 1 month | |
Secondary | Hemoglobine rate variation | For patients having no received blood transfusion, the hemoglobine rate variation is assessed in percentage at one month in post-surgery. | 1 month | |
Secondary | Positive surgical margins | Number of positive surgical margins | 1 month | |
Secondary | Variation between global GFR in the two groups | The variation of the global GFR is assessed after surgery, when patient is discharged. This value is compared to the that collected before the surgery. | 6 months | |
Secondary | Renal parenchyma preserved | The percentage of renal parenchyma preserved is evaluated by CT renal volumetry at 6 months after the surgery. The value is compared to that collected before the surgery. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 |